New report predicts both clinical risk and tumor aggressiveness

The Oncotype DX Genomic Prostate Score provides a comprehensive risk profile for personalized information to guide treatment decisions.

Oncotype DX GPS is proven to be an independent predictor of:

Clinical risk

  • Prospectively validated as an independent predictor of both prostate cancer death and metastasis at 10 years1*
  • Predicts future tumor behavior and helps patients understand long-term prognosis to ease patient concerns and offer reassurance1

Tumor aggressiveness

  • Prospectively validated as an independent predictor of adverse pathology2,3†
  • The most important and actionable endpoint when individualizing patient management4,5
  • Identifies patients with less aggressive disease who are likely candidates for Active Surveillance

1. Van Den Eeden et al. AUA 2017. Abstract MP20-05.
2. Klein et al. Eur Urol. 2014.
3. Cullen et al. Eur Urol. 2014.
4. Kozminski et al. Eur Oncol. 2016.
5. Eggener et al. J Urol. 2011.

a. DOI: 10.1016/j.eururo.2017.09.013

* Kaiser Permanente Northern California (KPNC) retrospective cohort study N=279 clinically low, intermediate, and high risk patients; biopsy.
† University of California, San Francisco (UCSF) prospective validation study: N=395 clinically low-risk patients; needle biopsy.
‡ Center for Prostate Disease Research (CPDR) prospective validation study: N=402 clinically low-risk patients; needle biopsy.

Do You Have a Question?

Contact Us

Clinical Validation:

Kaiser Permanente of Northern California assessed the association between GPS and two hard endpoints: metastasis and prostate cancer death in a cohort of 267 men.

Read Full Text

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™